Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction

Transfusion

Volumn 50, Issue 6, 2010, Pages 1285-1294

  Katsman, Yulia ^a,b   Foo, Alison H ^a,b   Leontyev, Danila ^a,b   Branch, Donald R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TER 119; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG MECHANISM; FEMALE; IMMUNE MEDIATED INJURY; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; WHOLE BODY RADIATION;

ANIMALS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; FEMALE; GAMMA RAYS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED BALB C; MICE, SCID; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOPOIESIS; TIME FACTORS; WHOLE-BODY IRRADIATION;

EID: 77953108625     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02558.x     Document Type: Article

References (36)

1. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Sem Haematol 2000 37 : 239 48. (Pubitemid 30612902)
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002 346 : 995 1008.
3. Bussel JB, Hilgartner MW. The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Br J Haematol 1984 56 : 1 7.
4. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Haematology. Blood 1996 88 : 3 40.
5. Parodi E, Rivetti E, Amendola G, Bisogno G, Calabrese R, Farruggia P, Giordano P, Matarese SM, Nardi M, Nobili B, Notarangelo LD, Russo G, Vimercati C, Zecca M, De Mattia D, Ramenghi U. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP:identification of factors predictive of a sustained response. Br J Haematol 2009 144 : 552 58.
6. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981 36 : 81 6. (Pubitemid 11137811)
7. Imbach P, Barandun S, Hirt A, Wagner HP. Intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP) in childhood. Am J Pediatr Haematol Oncol 1984 6 : 171 74.
8. Bussel JB. The use of intravenous gama-globulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 1989 53 : S147 S155.
9. Shad AT, Gonzalez CE, Sandler SG. Treatment of immune thrombocytopenic purpura in children: current concepts. Paediatr Drugs 2005 7 : 325 26.
10. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005 115 : 155 60.
11. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of antiidiotype reactivity. Br J Haematol 2001 115 : 679 86.
12. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992 98 : 637 46.
13. Semple JW, Siminovich KA, Mody M, Milev Y, Lazarus AH, Wright JF, Freedman J. Flow cytometric analysis of platelets from children with the Wiskott-Aldrich syndrome reveals defects in platelet development, activation and structure. Br J Haematol 1997 97 : 747 54.
14. Karpatkin S, Garg SK, Siskind GW. Autoimmune thrombocytopenic purpura and the compensated thrombocytolytic state. Am J Med 1971 51 : 1 4.
15. Rodriguez AR. Compensated thrombocytolytic state. South Med J 1980 73 : 823 4.
16. Debili N, Robin C, Schiavon V, Letestu R, Pflumio F, Mitjavila-Garcia MT, Coulombel L, Vainchenker W. Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates. Blood 2001 97 : 2023 30. (Pubitemid 32239082)
17. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995 23 : 996 1001.
18. Manning KL, McDonald TP. C3H mice have larger spleens, lower platelet counts, and shorter platelet lifespans than C57BL mice: an animal model for the study of hypersplenism. Exp Haematol 1997 25 : 1019 24.
19. Crow AR, Song S, Freedman J, Helgason CD, Humphries RK, Siminovitch KA, Lazarus AH. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003 102 : 558 60.
20. Kina T, Ikuta K, Takayama E, Wada K, Majumdar AS, Weissman IL, Katsura Y. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol 2000 109 : 280 87.
21. Nandurkar HH, Robb L, Tarlinton D, Barnett L, Kontgen F, Begley CG. Adult mice with targeted mutation of the interleukin-11 receptor (IL-11Ra) display normal hematopoiesis. Blood 1997 90 : 2148 59.
22. Penny R, Rozenberg MC, Firkin BC. The splenic platelet pool. Blood 1966 27 : 1 16.
23. Stenberg PE, Levin J. Ultrastructural analysis of acute immune thrombocytopenia in mice: dissociation between alterations in megakaryocytes and platelets. J Cell Physiol 1989 141 : 160 9.
24. Liepkalns J, Hod E, Spitalnik SL, Cadwell C, Zimring J. Characterization of hemolysis resistance during crossmatch incompatible transfusion in a mouse model. Transfusion 2008 48 : S14 010C.
25. Gallicchio VS. Accelerated recovery of hematopoiesis following sub-lethal whole body irradiation with recombinant murine interleukin-1 (IL-1). J Leuk Biol 1988 43 : 211 15.
26. Chang M, Suen Y, Meng G, Buzby JS, Bussel J, Shen V, van de Ven C, Cairo MS. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood 1996 88 : 3354 62.
27. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 291 : 484 6.
28. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2009 212 : 8 27.
29. Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006 12 : 688 92.
30. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialyation. Science 2006 313 : 670 3.
31. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003 101 : 3708 13.
32. Song S, Crow AR, Siragam V, Freedman J, Lazarus AH. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005 105 : 1546 8.
33. Panasiuk A, Prokopowicz D, Zak J, Panasiuk B. Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis; relation to thrombopoietin and hepatocyte growth factor serum concentration. Hepatogastroenterology 2004 51 : 1124 8.
34. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, Bleeker WK. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001 98 : 1095 9.
35. Deng R, Balthasar JP. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood 2007 109 : 2470 6.
36. Blanchette VS, Carcao M. Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura. Trans Sci 1998 19 : 279 88.